Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2019 08:03 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Give Webcast Presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019

PITTSBURGH, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
November 04, 2019 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Expands Leadership Team with Appointment of James M. O’Brien as Chief Financial Officer

PITTSBURGH, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
October 10, 2019 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Present Findings from the Elayta™ Clinical Development Program at Society for Neuroscience Annual Meeting

Pittsburgh, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
July 24, 2019 09:27 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China

Pittsburgh, July 24, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
March 26, 2019 09:51 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors

Pittsburgh, March 26, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
February 21, 2019 08:03 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives European Patent Covering its Alzheimer's Disease Candidate, Elayta™

Pittsburgh, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
February 19, 2019 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™

Pittsburgh, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
November 27, 2018 08:03 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease

Pittsburgh, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
October 24, 2018 11:40 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Sponsor Third International Symposium on Sigma-2 Receptors: Role in Health and Disease during the Society for Neuroscience Annual Meeting

Pittsburgh, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other...